CD19 and lymphoma: To date, most progress has been made in the treatment of hematologic malignancy, with cord blood NK cells engineered to express a CD19-targeting CAR demonstrating high response rates in patients with relapsed CD19+ leukemia or lymphoma (Liu et al., 2020).